The two drugs involved work in strikingly different ways. Escitalopram oxalate belongs to the selective serotonin reuptake inhibitor (SSRI) family, a class that raises serotonin levels in the brain by blocking its reabsorption, thereby strengthening serotonergic signaling. It is widely prescribed for depression and anxiety because of its high tolerability and selectivity. Bupropion hydrochloride, by contrast, is an atypical antidepressant classified as a norepinephrine–dopamine reuptake inhibitor, or NDRI. By preventing the reuptake of norepinephrine and dopamine, it boosts extracellular levels of these monoamine neurotransmitters and increases noradrenergic and dopaminergic neurotransmission, ultimately raising postsynaptic neuronal activity. The fixed-dose combination of the two was approved in April 2017 and has since been used to manage mood disorders, offering clinicians a way to target multiple neurotransmitter systems at once.

Measuring both compounds in one tablet, however, is not trivial. The two molecules differ in polarity, concentration ratio, and chemical behavior, and a synthetic tablet typically contains a large excess of bupropion relative to escitalopram. In the new method, the researchers dissolved a quantity of synthetic mixture equivalent to 10 milligrams of escitalopram and 150 milligrams of bupropion in methanol, sonicated it for 15 to 20 minutes to ensure complete extraction, filtered the solution through a 0.45-micrometer membrane, and diluted it to yield a final sample containing 1 microgram per milliliter of escitalopram and 15 micrograms per milliliter of bupropion. That 1:15 ratio is a demanding test for any chromatographic method, because the detector must remain linear across very different concentration ranges for the two analytes.

The chromatographic conditions the team settled on are elegantly simple. Separation was achieved on a C18 column measuring 250 by 4.6 millimeters with 5-micrometer particles, using a mobile phase of acetonitrile and phosphate buffer at pH 3, adjusted with orthophosphoric acid, in a 75:25 volume ratio. The system ran under isocratic elution, meaning the solvent composition stays constant throughout the run, at a flow rate of 1.0 milliliter per minute with a 10-microliter injection volume and detection at 233 nanometers using a photodiode array detector. The column temperature was held at 30 degrees Celsius. Under these conditions, escitalopram eluted first, at about 4.2 minutes, followed by bupropion at about 7.7 minutes. The order makes physical sense: the more polar escitalopram has a stronger affinity for the polar mobile phase and spends less time interacting with the non-polar stationary phase, while the less polar bupropion lingers longer on the hydrophobic C18 surface before washing off.

Reaching that clean separation took systematic optimization. The researchers experimented with different solvents, pH levels, and solvent compositions before landing on the acidic acetonitrile–buffer blend. Ultraviolet spectra of both drugs were recorded between 200 and 400 nanometers to choose a wavelength at which both compounds absorb strongly enough for simultaneous detection, and 233 nanometers emerged as the best compromise. The resulting chromatograms showed well-resolved, symmetrical peaks without significant tailing, and system suitability testing confirmed healthy values for resolution, tailing factor, and theoretical plates, the classic metrics chromatographers use to judge whether a system is performing properly before trusting any data it produces.

Validation followed the international ICH Q2(R1) guideline, the industry standard for analytical procedure validation. Linearity was demonstrated for escitalopram across 1 to 6 micrograms per milliliter and for bupropion across 15 to 90 micrograms per milliliter, with correlation coefficients of 0.999 in both cases, meaning the detector response rose almost perfectly in proportion to concentration. Accuracy, assessed through recovery experiments, ranged from 98.51 to 100.33 percent for escitalopram and 99.05 to 100.23 percent for bupropion, figures comfortably within the narrow windows regulators expect. Precision was evaluated as repeatability, intraday, and interday variability expressed as relative standard deviation, and all values came in below 2 percent, indicating the method produces consistent results regardless of when or how the measurements are made within a day or across days.

The method also proved sensitive enough for its purpose. Limits of detection, calculated using the ICH equations LOD = 3.3σ/S and LOQ = 10σ/S, where σ is the standard deviation of the response and S the slope of the calibration curve, came out at 0.101 micrograms per milliliter for escitalopram and 1.188 micrograms per milliliter for bupropion. The corresponding limits of quantification were 0.308 and 3.602 micrograms per milliliter, respectively. Specificity testing added another layer of confidence: when blank solutions were analyzed, no interfering peaks appeared at the retention times of either drug, showing that common tablet excipients would not distort the results. Robustness and ruggedness studies, in which chromatographic conditions were deliberately varied, confirmed that retention times and peak areas held steady, meaning the method tolerates small everyday fluctuations in a quality-control laboratory.

When the team applied the method to a synthetic mixture containing 10 milligrams of escitalopram and 150 milligrams of bupropion, the assay recovered 99.98 percent of the escitalopram and 99.94 percent of the bupropion. That near-perfect recovery, combined with the confirmation that additives in the mixture did not disrupt the analysis, demonstrates that the approach is ready for real-world formulation testing. The authors note that the method offers simple chromatographic conditions, rapid analysis, and simultaneous estimation of both drugs at a single wavelength, a combination that translates directly into lower costs and faster turnaround times for pharmaceutical quality-control labs that must analyze thousands of samples.

Why does this matter beyond the laboratory bench? Fixed-dose combination antidepressants sit at the intersection of pharmacology and manufacturing, and every batch that reaches patients depends on validated analytical methods like this one. The literature already contains numerous chromatographic techniques for bupropion and escitalopram individually or paired with other drugs such as clonazepam, etizolam, naltrexone, or aripiprazole, but each new approved combination demands its own validated method tuned to the specific ratio and properties of the drugs involved. By providing a straightforward, reproducible RP-HPLC procedure validated to ICH standards for the escitalopram–bupropion pair, Solanki and Dedania have given manufacturers and regulators a practical tool for routine quality control. It is a reminder that behind every psychiatric prescription lies a web of unglamorous but essential chemistry, ensuring that the pill in the bottle delivers precisely what the label promises.

Subject of Research: Development and validation of an RP-HPLC method for simultaneous quantification of escitalopram oxalate and bupropion hydrochloride in pharmaceutical formulations

Article Title: RP-HPLC method for the simultaneous estimation of escitalopram oxalate and bupropion hydrochloride used for treatment of mood disorder

Article References: Solanki, D., & Dedania, Z. (2026). RP-HPLC method for the simultaneous estimation of escitalopram oxalate and bupropion hydrochloride used for treatment of mood disorder. Discover Chemistry, 3(1), Article 576. https://doi.org/10.1007/s44371-026-01025-5

Image Credits: AI Generated

DOI: 10.1007/s44371-026-01025-5

Keywords: RP-HPLC, escitalopram oxalate, bupropion hydrochloride, method validation, ICH guidelines, antidepressants, mood disorders, pharmaceutical analysis, quality control, chromatography, SSRI, NDRI

The stakes behind this seemingly technical achievement are considerable. Impurity control sits at the heart of pharmaceutical safety: trace contaminants that slip past inadequate analytical methods can compromise therapeutic efficacy or, in the worst cases, pose direct risks to patients. Sertraline, chemically known as (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine hydrochloride, is a selective serotonin reuptake inhibitor that works by blocking serotonin reabsorption at presynaptic nerve terminals, enhancing neurotransmission in the central nervous system. During its synthetic preparation, structurally related impurities can arise, and regulators such as the International Council for Harmonisation require comprehensive impurity profiling and stability evaluation to guarantee product quality throughout a medicine’s shelf life.

Existing methods for sertraline impurity testing, the authors note, have been limited by empirical optimization, long run times, high solvent consumption, inadequate impurity resolution, and limited robustness. The drug substance is official in both the United States Pharmacopoeia and the European Pharmacopoeia, yet the pharmacopeial approaches rely on gas chromatography for specified organic impurities. The research team set out to close this gap by combining two modern paradigms: Analytical Quality by Design, often abbreviated AQbD, which applies systematic, risk-based experimentation to analytical method development, and Green Analytical Chemistry, which seeks to minimize the environmental footprint of laboratory work.

The journey to the final method was one of iterative refinement. Early attempts using an isocratic elution of potassium dihydrogen phosphate and acetonitrile on a conventional column failed entirely, with all impurity peaks eluting at the same retention time. Switching to methanol improved matters only marginally, producing broad peaks, while gradient programs and a phenyl column achieved separation but with unsatisfactory peak shapes caused by isomeric compounds. The breakthrough came with a pentafluorophenyl-modified C18 column, the ACE 5 C18 PFP, whose special surface chemistry offers multiple retention mechanisms, including hydrophobic, pi-pi, dipole-dipole, and hydrogen-bonding interactions, providing enhanced selectivity for structurally similar aromatic impurities that defeat ordinary C18 columns.

The optimized method uses a gradient of two mobile phases built around a 20 millimolar ammonium phosphate buffer adjusted to pH 4.2, mixed with methanol and acetonitrile in carefully tuned ratios. Mobile phase A combines buffer, methanol, and acetonitrile at 80:10:10, while mobile phase B blends methanol, acetonitrile, and buffer at 50:20:30. Separation proceeds on the 250 by 4.6 millimeter column at 40 degrees Celsius with a flow rate of 1.0 milliliter per minute and ultraviolet detection at 254 nanometers. Under these conditions, the six impurities elute at distinct retention times ranging from roughly 4 minutes for impurity-E to nearly 42 minutes for impurity-F, with sertraline itself appearing at about 22 minutes, all fully resolved from blank and placebo signals.

Crucially, the team did not simply tune parameters by trial and error. They identified column temperature and flow rate as critical method parameters and subjected them to a three-level, two-factor Design of Experiments, running thirteen HPLC experiments and modeling the results with response surface methodology. Statistical analysis confirmed that neither variable significantly affected the relative retention times of the key impurities, establishing a design space within which the method remains reliable. This systematic approach, validated against ICH Q2(R2) guidelines, demonstrated excellent linearity across concentration ranges of approximately 0.2 to 5.0 micrograms per milliliter with correlation coefficients exceeding 0.999, precision with relative standard deviations below 2 percent, and recoveries between 99.0 and 103.0 percent.

The method’s stability-indicating power was tested through forced degradation studies that subjected sertraline capsules to acidic, alkaline, oxidative, hydrolytic, thermal, photolytic, and humidity stress. Samples were treated with hydrochloric acid or sodium hydroxide at 60 degrees Celsius, exposed to 10 percent hydrogen peroxide, irradiated with more than 1.2 million lux hours of light per ICH Q1B, heated to 100 degrees Celsius for three days, or held at 90 percent relative humidity. Sertraline proved remarkably stable, with only limited degradation observed under all conditions. Where degradation products did form, they were cleanly resolved from the analyte peak, and photodiode array peak purity analysis confirmed the sertraline peak remained spectrally homogeneous, with satisfactory mass balance values throughout.

Perhaps the most distinctive feature of the study is its environmental assessment. Using two established greenness metrics, the AGREE analytical tool and the Green Analytical Procedure Index, the researchers scored their method at 0.79 and 84 respectively, indicating high environmental compatibility. The method earns green ratings for low sample consumption, minimal preparation steps, automation, avoidance of derivatization, waste control, and energy efficiency. In an era when laboratories worldwide are under pressure to reduce their reliance on hazardous solvents, the deliberate balancing of acetonitrile consumption against chromatographic performance represents a meaningful step toward sustainable pharmaceutical quality control.

The researchers report that sample and mobile phase solutions remained stable for up to 72 hours at room temperature, further supporting the method’s suitability for routine work. With its combination of complete impurity resolution, regulatory-compliant validation, statistically proven robustness, and favorable environmental profile, the AQbD-driven method offers pharmaceutical manufacturers a practical tool for both routine quality control and formal stability testing of sertraline capsules. As analytical laboratories increasingly embrace Quality by Design thinking and green chemistry principles, this study offers a template for how the two movements can converge, transforming the humble chromatogram into evidence of both patient safety and environmental responsibility.

Subject of Research: Development of a stability-indicating RP-HPLC method with Analytical Quality by Design and greenness assessment for quantifying impurities in sertraline hydrochloride dosage forms

Article Title: A stability-indicating RP-HPLC method for quantification of impurities in sertraline hydrochloride finished dosage forms using quality by design with environmental assessment

Article References: Bypaneni, V., Pinnenti, M. K., Temmanaboyina, G., Sambu, P., & Nagisetti, B. M. K. (2026). A stability-indicating RP-HPLC method for quantification of impurities in sertraline hydrochloride finished dosage forms using quality by design with environmental assessment. Discover Chemistry, 3(1), Article 569. https://doi.org/10.1007/s44371-026-01010-y

Image Credits: AI Generated

DOI: 10.1007/s44371-026-01010-y

Keywords: sertraline hydrochloride, RP-HPLC, Analytical Quality by Design, impurity profiling, forced degradation, green analytical chemistry, AGREE, GAPI, pharmaceutical quality control, stability-indicating method, chromatography, antidepressants

The triple combination is becoming increasingly common in the management of type 2 diabetes, and for good reason. Each drug attacks high blood sugar through a different biological route: metformin suppresses glucose production in the liver and improves insulin sensitivity, gliclazide prods the pancreas to release more insulin, and dapagliflozin forces the kidneys to flush excess glucose out through the urine. Combining them in a single pill improves patient compliance and delivers better glycaemic control than any one agent alone. But that therapeutic synergy creates an analytical headache, because a quality-control laboratory must be able to verify the exact amount of each ingredient in every batch before the tablets reach patients.

The difficulty lies in chemistry. Metformin is a small, strongly polar, highly hydrophilic molecule with a log P value of roughly minus 2.64, which means it barely interacts with the oily, hydrophobic surface of a reverse-phase column and tends to zip through unretained. Dapagliflozin and gliclazide, by contrast, are far more lipophilic, with log P values around 2 or higher, so they cling to the stationary phase much longer. On top of that, the dose disparity is enormous: commercial tablets contain 500 to 1000 milligrams of metformin, 40 to 80 milligrams of gliclazide, and a mere 5 to 10 milligrams of dapagliflozin, so any single method must accurately quantify compounds whose concentrations in solution differ by orders of magnitude.

Led by Rajendra Patel, with Nishith Teraiya and Anjali Prajapati, all of the K.B. Institute of Pharmaceutical Education and Research in Gandhinagar, the team systematically tuned every variable that governs chromatographic behavior. They tested water-methanol and water-acetonitrile mixtures in various ratios, but unbuffered systems produced broad, asymmetrical peaks with poor resolution. The breakthrough came from adding a volatile 20 millimolar ammonium acetate buffer adjusted to pH 3.0 with ortho-phosphoric acid. At that acidity, metformin remains fully protonated and water-loving, so it elutes first, while the more lipophilic dapagliflozin and gliclazide linger progressively longer on the hydrophobic C18 stationary phase, producing clean, well-resolved peaks.

The final recipe is elegantly simple. Separation occurs on a Kromasil C18 column, 250 millimeters long with a 4.6 millimeter internal diameter and 5 micrometer particles, using a mobile phase of the acetate buffer and acetonitrile mixed 35:65 by volume, pumped at a constant 0.8 milliliters per minute in isocratic mode. A UV detector set at 224 nanometers, a wavelength where the absorption spectra of all three drugs overlap acceptably, monitors the eluate. Under these conditions metformin appears at 2.47 minutes, dapagliflozin at 3.90 minutes, and gliclazide at 6.46 minutes. Because the solvent composition never changes during the run, the method avoids the complexity, variability, and extra solvent consumption of gradient elution, keeping both analysis time and operating costs low.

Validation followed the International Council for Harmonisation’s Q2 (R2) guidelines, the global benchmark for analytical procedures. Calibration curves were linear across 125 to 375 micrograms per milliliter for metformin, 2.5 to 7.5 for dapagliflozin, and 15 to 45 for gliclazide, with correlation coefficients all above 0.997. Recovery experiments, in which known amounts of standard drug were spiked into tablet samples at 80, 100, and 120 percent of target, yielded recoveries between 98 and 102 percent for every analyte, demonstrating negligible interference from tablet excipients. Precision testing, repeated within a single day and across three separate days, produced relative standard deviations consistently below 2 percent, the accepted threshold for repeatability in pharmaceutical analysis.

The robustness trials are particularly reassuring for routine laboratories. The researchers deliberately nudged the method’s settings, slightly altering mobile phase composition, flow rate, detection wavelength, buffer pH, and column temperature, and found that the separation held up every time, with peaks remaining symmetrical, well resolved, and statistically unchanged. Sample solutions stored for 48 hours at room temperature and at refrigerator temperature showed no degradation and no loss of assay value, meaning laboratories can prepare samples in advance without compromising results. Limits of detection and quantification, calculated from the regression statistics of the calibration lines, confirmed the method is sensitive enough for the low-dose dapagliflozin component.

The most dramatic evidence for the method’s stability-indicating power came from forced degradation studies, which regulators require to prove that an analytical method can spot decomposition before it spots nothing at all. The team exposed the drugs to 0.1 normal hydrochloric acid for one hour, 0.1 normal sodium hydroxide for two hours, 3 percent hydrogen peroxide for one hour, 40 degrees Celsius heat for one hour, and direct sunlight for two hours. Each stressor told a chemical story: gliclazide degraded most under acid, consistent with hydrolysis of its sulfonylurea linkage; dapagliflozin proved most vulnerable to light, its aromatic glucoside structure susceptible to photo-oxidation; and metformin, shielded by its highly polar biguanide scaffold, stayed comparatively stable even under heat. Crucially, in every case the degradation products eluted as separate peaks that never overlapped the three drug peaks.

Applied to a real commercial tablet containing 10 milligrams of dapagliflozin, 60 milligrams of gliclazide, and 500 milligrams of metformin, the method returned assay values of 101.52, 98.19, and 99.64 percent respectively, comfortably within pharmacopoeial expectations and confirming that the technique works outside the pristine world of pure standards. That real-world performance matters because regulators and manufacturers increasingly rely on such methods for batch release, shelf-life determination, and post-market surveillance. A method that is simultaneously accurate, robust, and stability-indicating gives quality-control chemists a single, streamlined workflow where they previously might have needed multiple runs or separate methods for each drug pair.

The broader significance extends past one formulation. As fixed-dose combinations multiply across modern pharmacotherapy, the analytical community faces growing pressure to verify ever more complex mixtures with fewer resources. This study demonstrates that careful exploitation of fundamental properties, lipophilicity, ionization state, and spectral overlap, can tame even a three-drug combination spanning a hundredfold dose range in a simple isocratic run. For the millions of patients taking triple antidiabetic therapy, the work represents an invisible but vital layer of assurance: every tablet’s contents can now be confirmed, and its chemical deterioration detected, in under seven minutes of chromatography.

Subject of Research: Development and validation of a stability-indicating RP-HPLC method for simultaneous quantification of dapagliflozin, gliclazide, and metformin in antidiabetic combination tablets

Article Title: Development of a robust stability-indicating RP-HPLC method for simultaneous estimation of triple antidiabetic combination containing dapagliflozin, gliclazide and metformin

Article References: Patel, R., Teraiya, N., & Prajapati, A. (2026). Development of a robust stability-indicating RP-HPLC method for simultaneous estimation of triple antidiabetic combination containing dapagliflozin, gliclazide and metformin. Discover Chemistry, 3(1), Article 518. https://doi.org/10.1007/s44371-026-00978-x

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00978-x

Keywords: RP-HPLC, dapagliflozin, gliclazide, metformin, type 2 diabetes, stability-indicating method, forced degradation, pharmaceutical analysis, ICH Q2 (R2), chromatography, quality control, fixed-dose combination